Zhou J, Zhang S, Xue J, Avery J, Wu J, Lind SE, Ding WQ

Activation of PPARα has been demonstrated to inhibit tumor growth and angiogenesis, yet the mechanisms behind these actions remain to be characterized. The present study examined the effects of PPARα activation on the HIF-1α signaling pathway in human breast (MCF-7) and ovarian (A2780) cancer cells under hypoxia. Incubation of cancer ...

Read More

cells under 1% oxygen for 16 hours significantly induced HIF-1α expression and activity as assayed with Western blot and reporter gene analysis. Treatment of the cells with PPARα agonists, but not a PPAR-agonist, prior to hypoxia diminished hypoxia-induced HIF-1α expression and activity, and addition of a PPARα antagonist attenuated the suppression of the HIF-1α signaling. Activation of PPARα attenuated hypoxia-induced HA-tagged HIF-1α protein expression without affecting the HA-tagged HIF-1α mutant protein level, indicating that PPARα activation promotes HIF-1α degradation in these cells. This was further confirmed by the use of proteasome inhibitors, which reversed PPARα-mediated suppression of the HIF-1α expression under hypoxia. Using the co-immunoprecipitation technique, we found that activation of PPARα enhances the binding of HIF-1α to Von Hippel-Lindau tumor suppressor (pVHL), a protein known to mediate HIF-1α degradation through the ubiquitin-proteasome pathway. Following PPARα-mediated suppression of HIF-1α signaling, vascular endothelial growth factor (VEGF) secretion from the cancer cells was significantly reduced, and tube formation by endothelial cells was dramatically impaired. Taken together, these findings demonstrate for the first time that activation of PPARα suppresses hypoxia-induced HIF-1α signaling in cancer cells, providing novel insight into the anticancer properties of PPARα agonists.

Date: Aug. 29, 2012

View in: Pubmed Google Scholar

142383